ClinicalTrials HQ

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Recruiting · NCT06174220 · Registry updated 2026-03-12
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic CardiomyopathyArrhythmias, Cardiac, Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Death, Death, Sudden, Death, Sudden, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arrhythmogenic right ventricular cardiomyopathy, cardiac arrest, cardiomyopathy, cardiovascular disorder, congenital heart disease, heart disorderRecruitingPhase 22026-03-12NCT06174220

6 results · Page 1 of 1

17 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Hamilton General HospitalHamiltonCanada38
Heart Health Institute Research IncScarborough VillageCanada1
Hopital du Sacré-Coeur de MontréalMontrealCanada2
Kingston General HospitalKingstonCanada12
London Health Sciences CentreLondonCanada28
McGill University Health CentreMontrealCanada69
Montreal Heart InstituteMontrealCanada49
Newmarket Electrophysiologist Research Group 'NERG'NewmarketCanada1
NL Health ServicesSt. John'sCanada2
Nova Scotia HealthHalifaxCanada4
St. Michael's HospitalTorontoCanada62
Sunnybrook Health Sciences CentreTorontoCanada167
University Institute of Cardiology and Pneumology of QuebecQuébecCanada1
University of British ColumbiaVancouverCanada5
University of CalgaryCalgaryCanada10
University of Ottawa Heart InstituteOttawaCanada61
Victoria Cardiac Arrhythmia Trials Inc.VictoriaCanada1